Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $262.6 million.

  • Ani Pharmaceuticals' Cash & Equivalents rose 8113.28% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 8113.28%. This contributed to the annual value of $144.9 million for FY2024, which is 3448.79% down from last year.
  • Ani Pharmaceuticals' Cash & Equivalents amounted to $262.6 million in Q3 2025, which was up 8113.28% from $217.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cash & Equivalents ranged from a high of $262.6 million in Q3 2025 and a low of $15.3 million during Q3 2021
  • Over the past 5 years, Ani Pharmaceuticals' median Cash & Equivalents value was $144.9 million (recorded in 2024), while the average stood at $128.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 117543.23% in 2021, then crashed by 5191.63% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Cash & Equivalents stood at $100.3 million in 2021, then tumbled by 51.92% to $48.2 million in 2022, then skyrocketed by 358.49% to $221.1 million in 2023, then plummeted by 34.49% to $144.9 million in 2024, then surged by 81.28% to $262.6 million in 2025.
  • Its Cash & Equivalents stands at $262.6 million for Q3 2025, versus $217.8 million for Q2 2025 and $149.8 million for Q1 2025.